241 related articles for article (PubMed ID: 19182207)
1. Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras.
Ghosh A; Koestner W; Hapke M; Schlaphoff V; Länger F; Baumann R; Koenecke C; Cornberg M; Welte K; Blazar BR; Sauer MG
Blood; 2009 Apr; 113(18):4440-8. PubMed ID: 19182207
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
3. Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versus-host disease after non T cell-depleted HLA-mismatched peripheral blood stem cell transplantation.
Wu BY; Guo KY; Song CY; Yang ; Li D
Bone Marrow Transplant; 2000 Sep; 26(6):691-3. PubMed ID: 11035376
[TBL] [Abstract][Full Text] [Related]
4. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism.
Mapara MY; Kim YM; Marx J; Sykes M
Transplantation; 2003 Jul; 76(2):297-305. PubMed ID: 12883182
[TBL] [Abstract][Full Text] [Related]
5. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells.
Mapara MY; Kim YM; Wang SP; Bronson R; Sachs DH; Sykes M
Blood; 2002 Sep; 100(5):1903-9. PubMed ID: 12176915
[TBL] [Abstract][Full Text] [Related]
6. Donor APCs are required for maximal GVHD but not for GVL.
Matte CC; Liu J; Cormier J; Anderson BE; Athanasiadis I; Jain D; McNiff J; Shlomchik WD
Nat Med; 2004 Sep; 10(9):987-92. PubMed ID: 15286785
[TBL] [Abstract][Full Text] [Related]
7. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.
Chakraverty R; Eom HS; Sachs J; Buchli J; Cotter P; Hsu R; Zhao G; Sykes M
Blood; 2006 Sep; 108(6):2106-13. PubMed ID: 16757687
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-leukemia effect in minor antigen mismatched chimeras given delayed donor leucocyte infusion: immunoregulatory aspects and role of donor T and ASGM1-positive cells.
Sefrioui H; Billiau AD; Waer M
Transplantation; 2000 Jul; 70(2):348-53. PubMed ID: 10933162
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
10. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
[TBL] [Abstract][Full Text] [Related]
11. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.
Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD
Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170
[TBL] [Abstract][Full Text] [Related]
12. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
13. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
14. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
[TBL] [Abstract][Full Text] [Related]
15. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses.
Reddy P; Maeda Y; Liu C; Krijanovski OI; Korngold R; Ferrara JL
Nat Med; 2005 Nov; 11(11):1244-9. PubMed ID: 16227991
[TBL] [Abstract][Full Text] [Related]
16. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants.
Billiau AD; Fevery S; Rutgeerts O; Landuyt W; Waer M
Blood; 2002 Sep; 100(5):1894-902. PubMed ID: 12176914
[TBL] [Abstract][Full Text] [Related]
17. The host environment regulates the function of CD8+ graft-versus-host-reactive effector cells.
Chakraverty R; Flutter B; Fallah-Arani F; Eom HS; Means T; Andreola G; Schwarte S; Buchli J; Cotter P; Zhao G; Sykes M
J Immunol; 2008 Nov; 181(10):6820-8. PubMed ID: 18981100
[TBL] [Abstract][Full Text] [Related]
18. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.
Sprangers B; Van Wijmeersch B; Fevery S; Waer M; Billiau AD
Nat Clin Pract Oncol; 2007 Jul; 4(7):404-14. PubMed ID: 17597705
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
[TBL] [Abstract][Full Text] [Related]
20. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
